AMPH PE Ratio & Valuation, Is AMPH Overvalued

Historical Valuation

Amphastar Pharmaceuticals, Inc (AMPH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 0.00 is considered Undervalued compared with the five-year average of 14.14. The fair price of Amphastar Pharmaceuticals, Inc (AMPH) is between +Inf to +Inf according to relative valuation method. Compared to the current price of 21.38 USD , Amphastar Pharmaceuticals, Inc By Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：21.38

Fair

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Amphastar Pharmaceuticals, Inc (AMPH) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Amphastar Pharmaceuticals, Inc (AMPH) has a current Price-to-Book (P/B) ratio of 1.24. Compared to its 3-year average P/B ratio of 2.80, the current P/B ratio is approximately -55.57% higher. Relative to its 5-year average P/B ratio of 2.81, the current P/B ratio is about -55.68% higher. Amphastar Pharmaceuticals, Inc (AMPH) has a Forward Free Cash Flow (FCF) yield of approximately 12.35%. Compared to its 3-year average FCF yield of 8.14%, the current FCF yield is approximately 51.69% lower. Relative to its 5-year average FCF yield of 6.92%, the current FCF yield is about 78.38% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AMPH competitors is 207.65, providing a benchmark for relative valuation. Amphastar Pharmaceuticals, Inc Corp (AMPH.O) exhibits a P/S ratio of 1.24, which is -99.4% above the industry average. Given its robust revenue growth of -1.83%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AMPH increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AMPH in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AMPH currently overvalued or undervalued?

Amphastar Pharmaceuticals, Inc (AMPH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 0.00 is considered Undervalued compared with the five-year average of 14.14. The fair price of Amphastar Pharmaceuticals, Inc (AMPH) is between +Inf to +Inf according to relative valuation method. Compared to the current price of 21.38 USD, Amphastar Pharmaceuticals, Inc is Undervalued By Fair.

What is Amphastar Pharmaceuticals, Inc (AMPH) fair value?

AMPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Amphastar Pharmaceuticals, Inc (AMPH) is between +Inf to +Inf according to relative valuation method.

How does AMPH's valuation metrics compare to the industry average?

The average P/S ratio for AMPH's competitors is 207.65, providing a benchmark for relative valuation. Amphastar Pharmaceuticals, Inc Corp (AMPH) exhibits a P/S ratio of 1.24, which is -99.40% above the industry average. Given its robust revenue growth of -1.83%, this premium appears unsustainable.

What is the current P/B ratio for Amphastar Pharmaceuticals, Inc (AMPH) as of Apr 16 2026?

As of Apr 16 2026, Amphastar Pharmaceuticals, Inc (AMPH) has a P/B ratio of 1.24. This indicates that the market values AMPH at 1.24 times its book value.

What is the current FCF Yield for Amphastar Pharmaceuticals, Inc (AMPH) as of Apr 16 2026?

As of Apr 16 2026, Amphastar Pharmaceuticals, Inc (AMPH) has a FCF Yield of 12.35%. This means that for every dollar of Amphastar Pharmaceuticals, Inc's market capitalization, the company generates 12.35 cents in free cash flow.

What is the current Forward P/E ratio for Amphastar Pharmaceuticals, Inc (AMPH) as of Apr 16 2026?

As of Apr 16 2026, Amphastar Pharmaceuticals, Inc (AMPH) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Amphastar Pharmaceuticals, Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Amphastar Pharmaceuticals, Inc (AMPH) as of Apr 16 2026?

As of Apr 16 2026, Amphastar Pharmaceuticals, Inc (AMPH) has a Forward P/S ratio of 1.24. This means the market is valuing AMPH at $1.24 for every dollar of expected revenue over the next 12 months.

AMPH Valuation